BG Negev Technologies and Applications, the technology transfer company of Ben Gurion University of the Negev, has raised $1 million from a US private equity fund, to develop therapies for neurodegenerative diseases. The funding will support a study conducted by the university’s Department of Immunology and Microbiology, which might be useful for prolonging lifespans for patients with diseases such as Amyotrophic Lateral Sclerosis (ALS). View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments